The clinical relevance of the distinct genomic landscape of KRAS oncogene in NSCLC might reveal specific therapeutic interventions [56], considering high levels of adenosine as a typical characteristic of tumor immune microenvironment (TIME) while having significant impact on both immune response and tumor cell growth. This evidence concerns the gene KRAS and non-small cell lung carcinoma.